"Regeneration To Slash Price Of Cholesterol Drug After Showing It Saved Lives" - Ben Fidler
Regeneron Pharmaceuticals and partner Sanofi report new data a large, highly-anticipated trial suggesting that their drug alirocumab (Praluent) may reduce the risk of death for people with high cholesterol who have recently suffered heart attacks or strokes and are at risk of having another one or dying. Doctors say this finding, though not statistically clear-cut, could still drive greater adoption of the expensive cholesterol drug. "I don't have a single patient on a PCSK9 inhibitor," said Roxana Mehran, MD, professor of medicine, cardiology, population health science and policy, and director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Weiner Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai.
- Roxana Mehran, MD, Professor, Medicine, Cardiology, Population Health Science and Policy, Director, Interventional Cardiovascular Research and Clinical Trials, Zena and Michael A. Weiner Cardiovascular Institute, Icahn School of Medicine at Mount Sinai